Disease Domain | Count |
---|---|
Neoplasms | 4 |
Top 5 Drug Type | Count |
---|---|
Vaccine | 2 |
Therapeutic vaccine | 1 |
Biological products | 1 |
Top 5 Target | Count |
---|---|
HER2 x MAGEA1 x TERT | 1 |
HER2 x HLA-A 24 | 1 |
Target |
Mechanism HER2 antagonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2014 |
Sponsor / Collaborator |
Start Date13 Sep 2012 |
Sponsor / Collaborator |
Start Date01 Aug 2012 |
Sponsor / Collaborator |